ImmunityBio (IBRX) Cash & Current Investments (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Cash & Current Investments data on file, last reported at $380.9 million in Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 518.4% year-over-year to $380.9 million in Q1 2026; TTM through Mar 2026 was $380.9 million, a 518.4% increase from a year earlier, with the FY2025 full-year figure at $242.8 million, up 62.09% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $380.9 million, up from $242.8 million in the prior quarter.
• Over the last five years, Cash & Current Investments for IBRX reached as high as $380.9 million in Q1 2026 and fell as low as $46.0 million in Q2 2023.
• Historically, Cash & Current Investments has averaged $167.8 million across 5 years, with a median of $153.7 million in 2025.
• Across the five-year window, Cash & Current Investments plunged 66.2% in 2022 and surged 518.4% in 2026, its largest moves.
• Year by year, Cash & Current Investments stood at $107.2 million in 2022, then jumped by 148.6% to $266.5 million in 2023, then tumbled by 43.78% to $149.8 million in 2024, then jumped by 62.09% to $242.8 million in 2025, then jumped by 56.86% to $380.9 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $380.9 million in Q1 2026, $242.8 million in Q4 2025, and $257.8 million in Q3 2025.